NCT04441606

The Role of 68Ga-FAPI-04 PET/CT as a Problem Solving Imaging Modality in Various Malignancies

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Tel-Aviv Sourasky Medical Center · Other Government
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

The aim of the suggested study is to assess the added value of 68Ga-FAPI-04 PET/CT over 18F-FDG PET/CT in evaluating the extent of disease in patients with various malignancies, in whom a diagnostic challenge is met, such as inconclusive findings on 18F-FDG PET/CT or other imaging studies, better delineation of tumor extent prior to therapy, and with emphasis on malignancies known to show variable avidity to FDG and at times, no uptake at all. Also patients unable to optimally comply with the required preparation for FDG imaging, such as diabetic patients who struggle in achieving glycemic control.

Conditions

• Different Types of Cancer

Interventions

Type	Name	Description
RADIATION	68Ga-FAPI-04 PET/CT	* Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days. * Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists. * Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression.

Timeline

• Start date: 2020-06-11
• Primary completion: 2020-06-17
• Completion: 2021-07-01
• First posted: 2020-06-22
• Last updated: 2021-02-11

Locations

1 site across 1 country: Israel